LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Regeneron Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

594.37 1.83

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

577.46

Max

594.92

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-109M

809M

Pardavimai

-761M

3B

P/E

Sektoriaus vid.

14.64

56.602

Pelnas, tenkantis vienai akcijai

8.22

Dividendų pajamingumas

0.67

Pelno marža

26.701

Darbuotojai

15,158

EBITDA

-54M

1B

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+40.88% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

0.67%

2.45%

Kitas uždarbis

2025-07-31

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-13B

62B

Ankstesnė atidarymo kaina

592.54

Ankstesnė uždarymo kaina

594.37

Naujienos nuotaikos

By Acuity

36%

64%

122 / 382 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Regeneron Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-04-29 11:07; UTC

Uždarbis

Regeneron 1Q Profit Rises, Revenue Falls; FY25 CapEx Target Trimmed

2025-02-04 12:13; UTC

Uždarbis

Regeneron 4Q Revenue Up on Strong Sales of EYLEA HD

2025-04-29 18:04; UTC

Rinkos pokalbiai
Uždarbis

Regeneron Sinks As Sales Of Key Eye Medication Tumble -- Market Talk

2025-04-29 14:39; UTC

Rinkos pokalbiai
Uždarbis

Regeneron's Eylea Setback Drags Stock as Investor Frustrations Mount -- Market Talk

2025-04-29 14:29; UTC

Uždarbis

Regeneron Stock Plummets After Earnings Miss -- Barrons.com

2025-04-29 13:11; UTC

Uždarbis

Regeneron Stock Plummets After Earnings Miss -- Barrons.com

2025-04-29 10:32; UTC

Uždarbis

Regeneron Pharma Cuts 2025 CapEx to $850M-$950M >REGN

2025-04-29 10:30; UTC

Uždarbis

Regeneron Pharma 1Q Rev $3.03B >REGN

2025-04-29 10:30; UTC

Uždarbis

Regeneron Pharma 1Q Net $808.7M >REGN

2025-04-29 10:30; UTC

Uždarbis

Regeneron Pharma 1Q EPS $7.27 >REGN

2025-04-29 10:30; UTC

Uždarbis

Regeneron Pharma 1Q Adj EPS $8.22 >REGN

2025-04-22 10:51; UTC

Svarbiausios naujienos

Drug Companies Step Up 'Make in America' Plans to Counter Tariffs -- WSJ

2025-02-28 12:00; UTC

Svarbiausios naujienos

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

2025-02-04 11:58; UTC

Uždarbis

Regeneron 4Q Rev Up on Strong Sales of EYLEA HD

2025-02-04 11:37; UTC

Uždarbis

Regeneron Pharma Sees 2025 Adjusted R&D $5B-$5.2B >REGN

2025-02-04 11:37; UTC

Uždarbis

Regeneron Pharma Sees 2025 Gross Margin on Net Product Sales 87%-88% >REGN

2025-02-04 11:36; UTC

Uždarbis

Regeneron Pharma Sees 2025 Capital Spending $850M-$975M >REGN

2025-02-04 11:35; UTC

Uždarbis

Regeneron Pharma Declares Initial Quarterly Dividend of 88c >REGN

2025-02-04 11:35; UTC

Uždarbis

Regeneron Pharma 4Q Adj EPS $12.07 >REGN

2025-02-04 11:34; UTC

Uždarbis

Regeneron Pharma 4Q U.S. Net Sales for Eylea HD, Eylea Rose 2% to $1.5B >REGN

2025-02-04 11:34; UTC

Uždarbis

Regeneron Pharma: 4Q Dupixent Global Net Sales Recorded by Sanofi Rose 15% to $3.7B >REGN

2025-02-04 11:32; UTC

Uždarbis

Regeneron Pharma Board OKs Additional $3 Billion Share Repurchase >REGN

2025-02-04 11:31; UTC

Uždarbis

Regeneron Pharma Initiates Quarterly Cash Dividend Program >REGN

2025-01-31 08:30; UTC

Įsigijimai, susijungimai, perėmimai

It's Bananas, but Stock Splits Can Pay Off. Here Are 5 Likely Contenders. -- Barrons.com

2025-01-28 10:30; UTC

Svarbiausios naujienos

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

2024-10-31 13:58; UTC

Uždarbis

Regeneron Takes A Ghastly Turn As High-Dose Eylea Lags And Biosimilars Loom -- IBD

2024-10-31 10:52; UTC

Uždarbis

Regeneron Earnings Top Views For Biotech Giant -- IBD

2024-10-31 10:34; UTC

Uždarbis

Regeneron Pharma 3Q Adj EPS $12.46 >REGN

2024-10-31 10:33; UTC

Uždarbis

Regeneron Pharma 3Q EPS Cut 43c by Acquired IPR&D Charge >REGN

2024-10-31 10:33; UTC

Uždarbis

Regeneron Pharma 3Q U.S. Sales for Eylea HD, Eylea Rose 3% to $1.54B >REGN

Akcijų palyginimas

Kainos pokytis

Regeneron Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

40.88% į viršų

12 mėnesių prognozė

Vidutinis 804.95 USD  40.88%

Aukščiausias 979 USD

Žemiausias 535 USD

Remiantis 21 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Regeneron Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

21 ratings

18

Pirkti

2

Laikyti

1

Parduoti

Techninis įvertinimas

By Trading Central

542.44 / 599.76Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Strong Bullish Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Rinkos nuotaikos

By Acuity

122 / 382 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.